These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 16289015

  • 1. The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
    Majumder S, Dutta P, Mookerjee A, Choudhuri SK.
    Chem Biol Interact; 2006 Feb 01; 159(2):90-103. PubMed ID: 16289015
    [Abstract] [Full Text] [Related]

  • 2. Overcoming drug-resistant cancer by a newly developed copper chelate through host-protective cytokine-mediated apoptosis.
    Mookerjee A, Mookerjee Basu J, Dutta P, Majumder S, Bhattacharyya S, Biswas J, Pal S, Mukherjee P, Raha S, Baral RN, Das T, Efferth T, Sa G, Roy S, Choudhuri SK.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 1):4339-49. PubMed ID: 16857809
    [Abstract] [Full Text] [Related]

  • 3. Iron N-(2-hydroxy acetophenone) glycinate (FeNG), a non-toxic glutathione depletor circumvents doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
    Ganguly A, Chakraborty P, Banerjee K, Chatterjee S, Basu S, Sarkar A, Chatterjee M, Choudhuri SK.
    Biometals; 2012 Feb 15; 25(1):149-63. PubMed ID: 21915630
    [Abstract] [Full Text] [Related]

  • 4. A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo.
    Mookerjee A, Basu JM, Majumder S, Chatterjee S, Panda GS, Dutta P, Pal S, Mukherjee P, Efferth T, Roy S, Choudhuri SK.
    BMC Cancer; 2006 Nov 15; 6():267. PubMed ID: 17107616
    [Abstract] [Full Text] [Related]

  • 5. Menadione reduced doxorubicin resistance in Ehrlich ascites carcinoma cells in vitro.
    Xu CJ, Zhang Y, Wang J, Zhang TM.
    Zhongguo Yao Li Xue Bao; 1998 May 15; 19(3):273-6. PubMed ID: 10375743
    [Abstract] [Full Text] [Related]

  • 6. Reversal of drug resistance in P-glycoprotein-expressing T-cell acute lymphoblastic CEM leukemia cells by copper N-(2-hydroxy acetophenone) glycinate and oxalyl bis (N-phenyl) hydroxamic acid.
    Majumder S, Dutta P, Mukherjee P, Datta ER, Efferth T, Bhattacharya S, Choudhuri SK.
    Cancer Lett; 2006 Nov 28; 244(1):16-23. PubMed ID: 16410038
    [Abstract] [Full Text] [Related]

  • 7. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U, Cao S, Minderman H, Toth K, Skenderis BS, Slovak ML, Rustum YM.
    Clin Cancer Res; 1996 Dec 28; 2(12):1961-8. PubMed ID: 9816155
    [Abstract] [Full Text] [Related]

  • 8. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
    Kisara S, Furusawa S, Murata R, Ogata M, Hikichi N, Takayanagi Y, Sasaki K.
    Oncol Res; 1995 Dec 28; 7(3-4):191-200. PubMed ID: 8555653
    [Abstract] [Full Text] [Related]

  • 9. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
    Lau DH, Lewis AD, Ehsan MN, Sikic BI.
    Cancer Res; 1991 Oct 01; 51(19):5181-7. PubMed ID: 1717140
    [Abstract] [Full Text] [Related]

  • 10. Reversal of resistance against doxorubicin by a newly developed compound, oxalyl bis(N-phenyl)hydroxamic acid in vitro.
    Choudhuri SK, Chatterjee A.
    Anticancer Drugs; 1998 Oct 01; 9(9):825-32. PubMed ID: 9840730
    [Abstract] [Full Text] [Related]

  • 11. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole.
    Desai PB, Duan J, Sridhar R, Damle BD.
    Methods Find Exp Clin Pharmacol; 1997 May 01; 19(4):231-9. PubMed ID: 9228648
    [Abstract] [Full Text] [Related]

  • 12. Importance of glutathione and associated enzymes in drug response.
    Shen H, Kauvar L, Tew KD.
    Oncol Res; 1997 May 01; 9(6-7):295-302. PubMed ID: 9406235
    [Abstract] [Full Text] [Related]

  • 13. Alterations in glutathione and glutathione-related enzymes in a multidrug-resistant small cell lung cancer cell line.
    Cole SP, Downes HF, Mirski SE, Clements DJ.
    Mol Pharmacol; 1990 Feb 01; 37(2):192-7. PubMed ID: 1968221
    [Abstract] [Full Text] [Related]

  • 14. Targeting the mitochondrial pathway to induce apoptosis/necrosis through ROS by a newly developed Schiff's base to overcome MDR in cancer.
    Basu S, Ganguly A, Chakraborty P, Sen R, Banerjee K, Chatterjee M, Efferth T, Choudhuri SK.
    Biochimie; 2012 Jan 01; 94(1):166-83. PubMed ID: 22037022
    [Abstract] [Full Text] [Related]

  • 15. The role of a Schiff base scaffold, N-(2-hydroxy acetophenone) glycinate-in overcoming multidrug resistance in cancer.
    Ganguly A, Chakraborty P, Banerjee K, Choudhuri SK.
    Eur J Pharm Sci; 2014 Jan 23; 51():96-109. PubMed ID: 24044945
    [Abstract] [Full Text] [Related]

  • 16. Redox active copper chelate overcomes multidrug resistance in T-lymphoblastic leukemia cell by triggering apoptosis.
    Ganguly A, Basu S, Banerjee K, Chakraborty P, Sarkar A, Chatterjee M, Chaudhuri SK.
    Mol Biosyst; 2011 May 23; 7(5):1701-12. PubMed ID: 21409205
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Overcoming multidrug resistance (MDR) in cancer in vitro and in vivo by a quinoline derivative.
    Ganguly A, Banerjee K, Chakraborty P, Das S, Sarkar A, Hazra A, Banerjee M, Maity A, Chatterjee M, Mondal NB, Choudhuri SK.
    Biomed Pharmacother; 2011 Sep 23; 65(6):387-94. PubMed ID: 21715129
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide--doxorubicin conjugate in vitro and in vivo.
    Ren Y, Wang Y, Zhang Y, Wei D.
    Mol Pharm; 2008 Sep 23; 5(4):579-87. PubMed ID: 18461970
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.